Sinopharm Group's (HKG:1099) profit attributable to owners of the parent fell 1.8% in the first six months of 2026 to 3.40 billion yuan from 3.47 billion yuan a year ago, according to a Monday filing to the Hong Kong stock exchange.

Earnings per share declined to 1.09 yuan from 1.11 yuan a year earlier, the pharmaceutical company said.

Revenue edged down 1.1% to 282.8 billion yuan from 286.04 billion yuan a year ago.